IPN Share Price

Open 108.65 Change Price %
High 110.10 1 Day 1.05 0.97
Low 108.55 1 Week 1.00 0.92
Close 109.50 1 Month -6.85 -5.89
Volume 109807 1 Year 50.70 86.22
52 Week High 129.85
52 Week Low 57.36
IPN Important Levels
Resistance 2 110.94
Resistance 1 110.34
Pivot 109.38
Support 1 108.66
Support 2 108.06
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
OXI 0.08 14.29%
OXI 0.08 14.29%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
GDMS 692.00 -10.00%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
CIB 0.10 -9.09%
MLZAM 1.65 -8.33%
MLOLM 10.50 -7.98%
HBW 0.15 -6.25%
ALPHY 13.00 -4.90%
JXR 0.62 -4.62%
More..

Ipsen (EPA: IPN)

IPN Technical Analysis 2
As on 16th Aug 2017 IPN Share Price closed @ 109.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 87.11 & Strong Sell for SHORT-TERM with Stoploss of 115.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPN Target for August
1st Target up-side 117.79
2nd Target up-side 124.47
3rd Target up-side 131.16
1st Target down-side 98.71
2nd Target down-side 92.03
3rd Target down-side 85.34
IPN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipsen.com
IPN Address
IPN
65, quai Georges Gorse
Cedex
Boulogne-Billancourt, 92650
France
Phone: 33 1 58 33 50 00
Fax: 33 1 58 33 50 01
IPN Latest News
Interactive Technical Analysis Chart Ipsen ( IPN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ipsen
IPN Business Profile
Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.